PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Journal of Immunology Research0 citationsOpen Access

Intermittent Tacrolimus Treatment Delays CD8+ Tumor‐Infiltrating Lymphocyte Exhaustion and Enhances PD1 Blockade Therapy in Melanoma‐Bearing Mice

View Full Paper
DCD. ChenSFSisi FengZCZ. Chen

Key Points

  • The research aims to investigate the effects of intermittent tacrolimus treatment on CD8+ T cell exhaustion and its interaction with PD1 blockade in melanoma models.
  • Melanoma-bearing mice received intermittent tacrolimus and/or PD1 blockade antibody.
  • T cell exhaustion was assessed using flow cytometry to measure inhibitory receptor expression.
  • Tumor growth rate and weight were monitored to evaluate treatment effectiveness.
  • Tumor-specific CD8+ T lymphocytes were identified using a peptide-based assay.
  • Intermittent tacrolimus and PD1 blockade increased functional CD8+ tumor-infiltrating lymphocytes.
  • Combined treatment significantly reduced tumor growth rate and weight compared to individual treatments.
  • Analysis showed increased expression of intermediate inhibitory receptors in CD8+ TILs with reduced high inhibitory receptors.
  • Tacrolimus improved CD8+ TIL response to melanoma-specific peptide.

Abstract

Continuous antigen exposure initiates the developmental process of CD8+ T cell exhaustion, accompanied by a gradual increase in the expression of inhibitory receptors (IRs). Our previous study conceptualized T cell exhaustion as an over‐activation status induced by chronic antigen stimuli. To intervene in the developmental process of CD8+ T cell exhaustion, we adjusted the over‐activation status by intermittently blocking T cell activation signals with tacrolimus, a T cell activation inhibitor. Melanoma‐bearing mice received intermittent tacrolimus (IT) and/or programmed cell death 1 (PD1) blockade antibody. Exhaustion phenotype of CD8+ tumor‐infiltrating lymphocytes (CD8+TILs) was detected by flow cytometry. The expression levels of IRs (PD1 and CD223), as well as memory markers (Ly108 and CD127), were utilized to demarcate the extent of CD8+TILs exhaustion. Then, tyrosinase‐related protein 2 peptide (Trp2 180–188 ) was used to detect tumor‐specific CD8+ TILs. Furthermore, tumor growth rate and tumor weight were also evaluated. We found that IT and/or PD1 blockade enhanced the infiltration of functional CD8+TILs. The findings demonstrated that both IT therapy and PD1 blockade enhanced the antitumor immunity. Combining IT and PD1 blockade led to a greater reduction in tumor growth rate and tumor weight. IT therapy also improved the response of CD8+TILs to melanoma‐specific Trp2 180–188 peptide. A detailed analysis of the CD8+TILs showed that Ly108 and CD127 reduced dramatically as the expression of PD1 increased. In comparison to PD1 blockade, combined treatment (IT plus PD1 blockade) significantly increased the number of intermediate IRs‐expressing CD8+TILs, while reducing the number of high IRs‐expressing CD8+TILs. These results indicated that combined treatment enhanced the function and decelerated the increase in IRs expression of CD8+TILs, deferring the developmental process of CD8+TILs exhaustion.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eee94https://doi.org/10.1155/jimr/8444562
Ask AI
Helpful
Bookmark
Share
View Full Paper